Avadel Pharmaceuticals Future Growth
Future criteria checks 6/6
Avadel Pharmaceuticals is forecast to grow earnings and revenue by 61.3% and 32.7% per annum respectively. EPS is expected to grow by 62.6% per annum. Return on equity is forecast to be 155.3% in 3 years.
Key information
61.3%
Earnings growth rate
62.6%
EPS growth rate
| Pharmaceuticals earnings growth | 21.4% |
| Revenue growth rate | 32.7% |
| Future return on equity | 155.3% |
| Analyst coverage | Good |
| Last updated | 15 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 400 | 166 | 189 | 151 | 6 |
| 12/31/2025 | 299 | 59 | 102 | 69 | 8 |
| 12/31/2024 | 168 | -48 | 16 | -54 | 9 |
| 3/31/2024 | 55 | -157 | -128 | -128 | N/A |
| 12/31/2023 | 28 | -160 | -129 | -129 | N/A |
| 9/30/2023 | 9 | -159 | -116 | -116 | N/A |
| 6/30/2023 | 1 | -143 | -85 | -84 | N/A |
| 3/31/2023 | N/A | -142 | -67 | -66 | N/A |
| 12/31/2022 | N/A | -137 | -71 | -70 | N/A |
| 9/30/2022 | N/A | -132 | -78 | -77 | N/A |
| 6/30/2022 | N/A | -134 | -92 | -92 | N/A |
| 3/31/2022 | N/A | -90 | -88 | -88 | N/A |
| 12/31/2021 | N/A | -77 | -77 | -77 | N/A |
| 9/30/2021 | N/A | -66 | -74 | -74 | N/A |
| 6/30/2021 | N/A | -56 | -63 | -63 | N/A |
| 3/31/2021 | 10 | -6 | -61 | -61 | N/A |
| 12/31/2020 | 22 | 7 | -49 | -49 | N/A |
| 9/30/2020 | 33 | 16 | -38 | -38 | N/A |
| 6/30/2020 | 48 | 18 | -35 | -35 | N/A |
| 3/31/2020 | 55 | -21 | -29 | -29 | N/A |
| 12/31/2019 | 59 | -33 | -38 | -38 | N/A |
| 9/30/2019 | 69 | -94 | -55 | -55 | N/A |
| 6/30/2019 | 75 | -101 | -68 | -67 | N/A |
| 3/31/2019 | 86 | -96 | -106 | -86 | N/A |
| 12/31/2018 | 103 | -95 | -103 | -83 | N/A |
| 9/30/2018 | 117 | -40 | -93 | -72 | N/A |
| 6/30/2018 | 137 | -2 | -128 | -55 | N/A |
| 3/31/2018 | 154 | 30 | -80 | -27 | N/A |
| 12/31/2017 | 173 | 68 | N/A | 17 | N/A |
| 9/30/2017 | 182 | 81 | N/A | 38 | N/A |
| 6/30/2017 | 174 | 40 | N/A | 37 | N/A |
| 3/31/2017 | 167 | -9 | N/A | 24 | N/A |
| 12/31/2016 | 150 | -41 | N/A | 19 | N/A |
| 9/30/2016 | 152 | 28 | N/A | 38 | N/A |
| 6/30/2016 | 167 | 19 | N/A | 61 | N/A |
| 3/31/2016 | 177 | 23 | N/A | 79 | N/A |
| 12/31/2015 | 173 | 42 | N/A | 84 | N/A |
| 9/30/2015 | 127 | -64 | N/A | 52 | N/A |
| 6/30/2015 | 87 | -46 | N/A | 36 | N/A |
| 3/31/2015 | 43 | -49 | N/A | 17 | N/A |
| 12/31/2014 | 15 | -89 | N/A | -11 | N/A |
| 9/30/2014 | 4 | -56 | N/A | -11 | N/A |
| 6/30/2014 | 2 | -52 | N/A | -15 | N/A |
| 3/31/2014 | 4 | -65 | N/A | -15 | N/A |
| 12/31/2013 | 4 | -47 | N/A | -21 | N/A |
| 9/30/2013 | 24 | -39 | N/A | -20 | N/A |
| 6/30/2013 | 23 | -39 | N/A | -25 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AWK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.7%).
Earnings vs Market: AWK is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AWK is expected to become profitable in the next 3 years.
Revenue vs Market: AWK's revenue (32.7% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: AWK's revenue (32.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AWK's Return on Equity is forecast to be very high in 3 years time (155.3%).